MRNA / Moderna revenue tops expectations, expects to return to sales growth in 2025

Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine dem more_horizontal

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons more_horizontal

While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its more_horizontal

Moderna (MRNA) shares tumbled over 6% Thursday after reporting a steep loss as the drug maker lost sales and cut back on making its COVID-19 vaccine, more_horizontal

Moderna, Inc. (NASDAQ:MRNA ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Rela more_horizontal

Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for th more_horizontal

CNBC's Becky Quick reports on the company's quarterly earnings results. more_horizontal

Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that more_horizontal